Ticagrelor monotherapy reduces bleeding risk following percutaneous coronary intervention
1. Clinically relevant bleeding was significantly lower with ticagrelor monotherapy than in the ticagrelor plus aspirin group. 2. Major cardiovascular and cerebrovascular events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Dual antiplatelet therapy (DAPT) is the current standard of care for acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI).